Mastodawn

The Daily Bolus: The Triple Agonist Showdown & Surprising GLP-1 Wins in Type 1 Diabetes
Welcome to today's edition of The Daily Bolus! The incretin landscape is rapidly evolving into the era of the "triple agonist," with Eli Lilly and Novo Nordisk going head-to-head to push weight loss and A1C reduction to new extremes. Meanwhile, groundbreaking real-wor
https://www.diabettech.com/the-daily-bolus-the-triple-agonist-showdown-surprising-glp-1-wins-in-type-1-diabetes/
#DailyBolus #Incretins

The Daily Bolus: The Triple Agonist Showdown & Surprising GLP-1 Wins in Type 1 Diabetes | Diabettech - Diabetes and Technology

Welcome to today's edition of The Daily Bolus! The incretin landscape is rapidly evolving into the era of the "triple agonist," with Eli Lilly and Novo Nordisk going head-to-head to push weight loss and A1C reduction to new extremes. Meanwhile, groundbreaking real-world data is showing that these blockbuster therapies are quietly transforming long-term care for

Diabettech - Diabetes and Technology | Where Diabetes and Technology meet

Tim Street Jun 11, 2025

Beyond Blood Sugar: Could incretins shield against diabetes complications?
Could incretins therapy effectively reduce the effects and thus risk of diabetes complications amongst all those with diabetes? A discussion of the mechanisms and actions that might lead t
https://www.diabettech.com/complications/beyond-blood-sugar-could-incretins-shield-against-diabetes-complications-2/
#complications #Incretins #DiabetesComplications #GLP1RA #Incretins #Mounjaro #Semaglutide #Tirzepatide #WeGovy

Beyond Blood Sugar: Could incretins shield against diabetes complications? | Diabettech - Diabetes and Technology

Could incretins therapy effectively reduce the effects and thus risk of diabetes complications amongst all those with diabetes? A discussion of the mechanisms and actions that might lead to this conclusion.

Diabettech - Diabetes and Technology | Where Diabetes and Technology meet